These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
278 related articles for article (PubMed ID: 8005104)
1. Expression of syndecan-1 is induced by differentiation and suppressed by malignant transformation of human keratinocytes. Inki P; Larjava H; Haapasalmi K; Miettinen HM; Grenman R; Jalkanen M Eur J Cell Biol; 1994 Feb; 63(1):43-51. PubMed ID: 8005104 [TBL] [Abstract][Full Text] [Related]
2. Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma. Mukunyadzi P; Liu K; Hanna EY; Suen JY; Fan CY Mod Pathol; 2003 Aug; 16(8):796-801. PubMed ID: 12920224 [TBL] [Abstract][Full Text] [Related]
3. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma. Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components. Tsanou E; Ioachim E; Briasoulis E; Charchanti A; Damala K; Karavasilis V; Pavlidis N; Agnantis NJ J Exp Clin Cancer Res; 2004 Dec; 23(4):641-50. PubMed ID: 15743035 [TBL] [Abstract][Full Text] [Related]
5. Expression of syndecan-1 changes during the differentiation of visceral and parietal endoderm from murine F9 teratocarcinoma cells. Jiang R; Kato M; Bernfield M; Grabel LB Differentiation; 1995 Nov; 59(4):225-33. PubMed ID: 8575644 [TBL] [Abstract][Full Text] [Related]
6. Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. Kumar-Singh S; Jacobs W; Dhaene K; Weyn B; Bogers J; Weyler J; Van Marck E J Pathol; 1998 Nov; 186(3):300-5. PubMed ID: 10211120 [TBL] [Abstract][Full Text] [Related]
7. Expression and characterization of minican, a recombinant syndecan-1 with extensively truncated core protein. Viklund L; Loo BM; Hermonen J; El-Darwish K; Jalkanen M; Salmivirta M Biochem Biophys Res Commun; 2002 Jan; 290(1):146-52. PubMed ID: 11779146 [TBL] [Abstract][Full Text] [Related]
8. Expression of syndecan in transformed mouse keratinocytes. Inki P; Gomez M; Quintanilla M; Cano A; Jalkanen M Lab Invest; 1992 Aug; 67(2):225-33. PubMed ID: 1501448 [TBL] [Abstract][Full Text] [Related]
9. Syndecan in carcinomas produced from transformed epithelial cells in nude mice. Inki P; Kujari H; Jalkanen M Lab Invest; 1992 Mar; 66(3):314-23. PubMed ID: 1538586 [TBL] [Abstract][Full Text] [Related]
10. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Anttonen A; Kajanti M; Heikkilä P; Jalkanen M; Joensuu H Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330 [TBL] [Abstract][Full Text] [Related]
11. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Matsuda K; Maruyama H; Guo F; Kleeff J; Itakura J; Matsumoto Y; Lander AD; Korc M Cancer Res; 2001 Jul; 61(14):5562-9. PubMed ID: 11454708 [TBL] [Abstract][Full Text] [Related]
12. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Inki P; Joensuu H; Grénman R; Klemi P; Jalkanen M Br J Cancer; 1994 Aug; 70(2):319-23. PubMed ID: 8054282 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical localization of syndecan in mouse skin tumors induced by UV irradiation. Loss of expression associated with malignant transformation. Inki P; Stenbäck F; Talve L; Jalkanen M Am J Pathol; 1991 Dec; 139(6):1333-40. PubMed ID: 1750507 [TBL] [Abstract][Full Text] [Related]